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Screening for abdominal aortic aneurysm
Remains effective and is likely to be cost effective in the UK, but data  
need to be monitored
A national NHS programme in England offers screen-
ing for abdominal aortic aneurysm in men aged 65, 
with the aim of reducing deaths from aneurysm rup-
ture.1 The key evidence underpinning this policy was 
the results of the multicentre aneurysm screening 
study (MASS), funded by the Medical Research Coun-
cil.2 More than 67 000 men aged 65-74 were recruited 
from four centres in the UK and were randomised to 
either receive or not receive an invitation to screening. 
The results after 4 years’ follow-up showed a 42% rela-
tive risk reduction in mortality related to abdominal 
aortic aneurysm (absolute risk reduction from 0.33% 
to 0.19%). An economic evaluation indicated that the 
investment in screening was close to being acceptably 
cost effective, even in the short term.3 
The evidence of clinical effectiveness was reinforced 
by a subsequent Cochrane Review—which estimated 
a 40% relative risk reduction (absolute risk reduction 
from 0.27% to 0.16%)—and then by results from MASS 
after 7 years’ follow-up.4 5 A formal long term eco-
nomic model built on the MASS data indicated that 
abdominal aortic aneurysm screening was likely to be 
extremely cost effective.6 Taken together, these find-
ings provided an unusually solid evidence base for a 
screening policy.
Two linked studies further add to the evidence 
base. 7 8 In the first study, Thompson and colleagues 
provide 10 year follow-up results from MASS, in 
which the relative risk reduction in mortality related 
to abdominal aortic aneurysm is maintained.7 They 
recalculate the original cost effectiveness estimates to 
account for this extended period of observation and 
now indicate an incremental cost effectiveness ratio of 
£7600 (€8800, $12 500; 95% CI £5100 to £13 000 
(€5900 to €15 000, $8350 to $21 300) per life year 
gained, much lower than the £20 000-30 000 threshold 
used by the National Institute for Health and  Clinical 
Evidence (NICE). On the other hand, the second 
linked study by Ehlers and colleagues presents a life-
time modelling study of a screening programme for 
abdominal aortic aneurysm and concludes that screen-
ing is not cost effective, with a mean cost per quality 
adjusted life year of £43 485.8 What is the reason for 
this discrepancy, particularly given that the modelling 
paper uses the previously published cost effectiveness 
evidence from MASS?
From the evidence in the papers as presented here, 
it is hard to identify the key reason for the differing 
findings or, more likely, the most important of  multiple 
contributory reasons. Importantly, the two papers 
agree that screening significantly reduces the number 
of deaths related to abdominal aortic aneurysm in the 
long term, although the Danish model suggests that 
there may be a small increase in net deaths in the 
short term. Ehlers and colleagues also argue, as have 
others,9 that a model that draws on all available data is 
inherently superior to a model based around one trial, 
albeit the biggest. Ehlers and colleagues have directly 
modelled the effects of the current policy of screening 
65 year olds, whereas the MASS results reflect a sam-
ple group screened at age 65-74.
The Danish authors do recognise, however, that 
there are other important differences between their 
long term cost effectiveness model and cost effective-
ness estimates based directly on MASS, including their 
use of Danish data on long term mortality after elec-
tive and emergency surgery. Possibly the key differ-
ence is the cost data used. Ehlers and colleagues used 
estimates of Danish costs that differed in important 
ways from the estimates originally in MASS—the costs 
of screening are higher in Denmark compared with 
the UK and the differential cost between elective and 
emergency surgery is substantially lower. Both these 
factors would make screening seem less cost effective. 
This is just one difference between the models, how-
ever, and cost effectiveness ratios are known to be rela-
tively unstable where the average difference in effect 
is small (at 10 years, an average additional survival of 
just 4.8 days per man invited to screening according 
to the MASS data).
Understanding fully the differences between  modelling 
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colour Doppler ultrasound scan of an aneurysm of the 
abdominal aorta showing circulating lumen of the artery 
(orange); the rest of the bulge is occupied by a clot (dark grey)
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Smoking in pregnancy
severe adverse effects can be avoided if smoking is stopped early 
The harm to infants of in utero exposure to tobacco 
smoke from maternal smoking is well established,1 2 
and a quarter of a century has passed since it was first 
shown in a clinical trial that stopping smoking during 
pregnancy could avoid the adverse effects of smoking 
on birth weight.3 The findings from the linked cohort 
study by McCowan and colleagues provide new obser-
vational evidence suggesting that for healthy women 
having their first baby, quitting smoking early in preg-
nancy (before 15 weeks’ gestation) can significantly 
reduce rates of spontaneous preterm birth, small for 
gestational age, and complicated pregnancies com-
pared to those of non-smokers.4 Continuing to smoke 
was associated with an almost threefold increase in the 
rate of spontaneous preterm birth (4%, 4%, and 10% 
for non-smokers, stopped smokers, and current smok-
ers, respectively) and a nearly twofold increase in the 
rate of small for gestational age infants (10%, 10%, and 
17%, respectively).
In the United States, up to 40% of women quit smok-
ing spontaneously before their first antenatal visit.2 5 6 
For the remainder, maximising the opportunity to pre-
vent the undesirable effects of smoking on outcomes 
in late pregnancy requires that maternity services have 
early contact with pregnant women. Recent guidelines 
from the National Institute for Health and Clinical 
Excellence (NICE) in the United Kingdom already 
suggest that women be booked for antenatal care ide-
ally by 10 weeks’ gestation.7
Although there is good evidence from a systematic 
review that interventions in pregnancy can reduce 
maternal smoking, cluster randomised trials of mid-
wife led interventions have not shown effectiveness. 
This disappointing finding is most likely because of 
the reservations midwives have about introducing the 
subject of stopping smoking in early antenatal visits, 
when they are trying to establish a positive relation-
ship with women.2 8 Being able to congratulate self-
motivated women who have ceased smoking by 15 
weeks’ gestation is one thing, but it is another task 
again to persuade continuing smokers of the benefits 
of smoking cessation.
We agree with McCowan and colleagues that encour-
aging women to quit smoking early in pregnancy 
should not be at the expense of efforts to assist women 
to stop smoking at any time during pregnancy. But we 
would go further and emphasise that reducing fetal 
and infant exposure to the harmful effects of tobacco 
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studies usually requires access to and exploration of the 
models—for example, by substituting alternative data and 
assumptions, and, most importantly in this case, incorpo-
rating into each the new 10 year MASS results. The need 
to explore what happens when parameter estimates and 
model structures are changed is why NICE insists on 
access to a  transparent working version of models when 
appraising new technologies. A compromise for journals 
would be to insist that much more detailed explanations 
of the models that underpin articles are made available 
on the internet.
So without such additional information and 
 analyses, what should we conclude about the cost 
effectiveness of screening for abdominal aortic aneu-
rysm? The 10 year results from MASS confirm that 
screening is effective in the long term, and there is 
no indication of the survival benefit being eroded. 
It would also seem reasonable to infer that a UK 
screening programme will be acceptably cost effec-
tive, providing that effectiveness can be maintained 
across the country and that the cost estimates remain 
relevant. These caveats emphasise that screening 
costs need to be controlled while quality is main-
tained, and that changes in the management of elec-
tive or emergency repair of aneurysms might have 
a significant impact. For example, as indicated in 
one of the sensitivity analyses in the Danish paper, 
the introduction of more costly endovascular repair 
might reduce the cost effectiveness of screening.9 
The accumulated evidence suggests that a national 
screening programme in the UK is appropriate and 
likely to be cost effective, but its costs and outcomes 
need to be carefully monitored and the data need to 
be regularly re-analysed to ensure that both the effec-
tiveness and cost effectiveness remain acceptable in 
the context of changing practice.
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smoke requires health professionals to encourage and 
assist both parents and other adults to cease smoking, 
and every opportunity should be taken to do this.
There is ample evidence that brief physician advice 
to stop smoking increases cessation rates by 1-3%, and 
further evidence indicates that more intensive counsel-
ling in healthcare settings will enable parents to stop 
smoking.9 10 Stopping parents smoking will reduce 
adverse pregnancy outcomes and improve their own 
health as well as that of their children. Given that paren-
tal smoking has been shown across the world to be 
the strongest predictor of children’s smoking, reducing 
parental smoking will also diminish the uptake of smok-
ing in adolescence. General practitioners, obstetricians, 
and midwives can also reinforce strategies for smoking 
control in their communities to reduce the initiation of 
smoking by young people. The National Institute for 
Health and Clinical Excellence has recently published 
guidance on mass media and point of sale measures 
for smoking cessation, and further guidance on school 
based interventions is to be published shortly.11
Persuading women to seek early antenatal care—
particularly those who are socioeconomically disad-
vantaged and hence most likely to be smoking—will 
not be easy. Exactly how compelling the evidence is 
from the cohort study of McCowan and colleagues, 
and whether the evidence justifies the resources neces-
sary to persuade women to seek early antenatal care 
should be questioned. The findings appear to be con-
sistent with much earlier work showing that perinatal 
mortality and mean birth weight for babies born to 
women who stopped smoking by four months’ gesta-
tion were almost the same as those for women who had 
never smoked.12 Smoking status in early pregnancy 
was the main exposure variable in this study, yet the 
study relied on self-reported data without biochemical 
verification, even though there is strong evidence from 
recent intervention trials that this method of data col-
lection is subject to important reporting bias.2
There is also the potential for residual confounding 
in McCowan and colleagues’ study, given the marked 
differences in social, demographic, and obstetric 
 characteristics between the non-smokers, stopped smok-
ers, and current smokers, although logistic regression 
analyses were performed. The data on pre-eclampsia 
rates would also have been useful, given the well estab-
lished although counter-intuitive association between 
smoking and a reduced risk of pre-eclampsia.
From a research perspective, these findings need 
verification both observationally using data from other 
birth cohort studies and empirically, ideally through 
trials of interventions to assist smoking cessation early 
in pregnancy that have spontaneous preterm birth and 
small for gestational age as the primary outcomes. In 
the meantime, there are plenty of evidence based steps 
that clinicians can take, which could contribute to a 
reduction in the involuntary exposure of nearly half 
the world’s children to harmful tobacco smoke.1
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Monitoring bone mineral density during antiresorptive 
treatment for osteoporosis
is potentially misleading and a misuse of healthcare resources
Antiresorptive treatment for osteoporosis is usually 
prescribed for a minimum of five years. Although it 
reduces the risk of fracture, it does not relieve symp-
toms caused by existing fractures and may have side 
effects. Understandably, therefore, patients and their 
doctors seek reassurance that the treatment is working. 
The most common way to monitor response is repeated 
measurement of bone mineral density using dual energy 
x ray absorptiometry (DXA), an approach endorsed by 
recent guidelines.1 2 Routine monitoring is costly, how-
ever, and—if it does not reduce disease burden—may 
divert healthcare resources away from more deserving 
causes. In the linked study, Bell and colleagues assess 
the need to monitor the response to bisphosphonate 
treatment by estimating how much the effects of alen-
dronate differ between individuals.3 
Treatment aims to reduce the rate of fractures; there-
fore, monitoring should detect whether treatment will 
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reduce the risk of fracture in individual patients. The 
effectiveness of repeated measurement of bone mineral 
density to monitor treatment depends on two prerequi-
sites. Firstly, the test used (DXA) should be able to detect 
a signifi cant change in bone mineral density within a 
time scale that enables effective changes in management 
to occur, and, secondly, the change in bone mineral den-
sity must predict the reduction in fractures after treat-
ment. If these criteria are not satisfi ed, patients may be 
misled and receive inappropriate advice. 
 To detect signifi cant changes in bone mineral density, 
the rate of bone gain must be larger than the preci-
sion error of the DXA measurement. Although this 
may be achieved after fi ve years of bisphosphonate or 
other antiresorptive drugs, the change in bone mineral 
density within the fi rst one or two years (when monitor-
ing is recommended by some guidelines) is generally 
too small to be detected. In everyday clinical practice, 
the precision of bone mineral density measurements 
is likely to be worse than in clinical trials, and even 
changes of 7% or more may not be reliably shown in 
individual patients. 4 Not being able to detect a change 
until fi ve years after the start of treatment is clearly not 
clinically useful; even one year is too long given the 
high rate of recurrent fractures in the fi rst 12 months 
after an incident fracture. 5 
 The study by Bell and colleagues analyses changes in 
bone mineral density during treatment with alendronate 
in a large randomised controlled trial, and it strengthens 
the case against routine monitoring during the fi rst few 
years of treatment. 3 Around 97.5% of women treated 
with alendronate showed an increase in hip bone min-
eral density of at least 0.019 g/cm 2 after three years, and 
the variation in the effect of treatment between women 
was considerably less than the within person variation 
on treatment. In other words, although nearly all women 
gain bone mineral density during treatment, the large 
variability associated with the measurement of bone 
mineral density obscures the true treatment response in 
the individual, which makes monitoring of bone mineral 
density unnecessary and potentially misleading. 
 The fi nal nail in the coffi n for monitoring bone min-
eral density is the observation that only a small propor-
tion of reduction in fractures attributable to treatment 
is explained by a change in bone mineral density. For 
example, only 16% and 4% of the decrease in the risk 
of fracture associated with treatment with alendronate 
or raloxifene, respectively, is attributable to an increase 
in bone mineral density. 6  7 Furthermore, some studies 
have found similar reductions in fracture regardless of 
whether bone mineral density increased or decreased 
on treatment. In postmenopausal women treated with 
risedronate, the reduction in non-vertebral fractures after 
three years of treatment was similar in women who lost 
or gained bone mineral density. 8 Similar fi ndings have 
been reported for the reduction in vertebral fractures in 
women treated with alendronate. 9 In the MORE study 
of raloxifene treatment, women in the treatment group 
with 4% bone loss in the hip had a lower risk of fracture 
than women in the placebo group who had a 4% gain 
in bone mineral density at this site. 7 How much these 
fi ndings refl ect variation in the measurement of bone 
mineral density or a true lack of correlation between 
changes in bone mineral density and fracture reduction 
is uncertain, but the clear implication for clinical prac-
tice is that patients may be given inappropriate advice 
if changes in bone mineral density are used to monitor 
treatment. 
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Reduced use of hormones and the drop in breast cancer
the lowest dose of hormones for the least amount of time should be used for the 
relief of menopausal flushes
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Recent studies have shown falls in the incidence of 
breast cancer in Australia and the United Kingdom.1 2 
This decline in hormone receptor positive tumours 
was found in post-menopausal women but not in pre-
menopausal women, and has also been noted across 
much of Europe and the United States.1 3 Most of these 
reports have linked this declining diagnosis of breast 
cancer to a decrease in use of hormone replacement 
therapy (HRT) following publication of the women’s 
health initiative study. The oestrogen plus progestogen 
arm of this study was halted in May 2002 because of 
an excess risk of breast cancer.4 
A subsequent US study that examined trends 
of breast cancer incidence and HRT use within a 
screened population likewise found a fall in the inci-
dence of breast cancer corresponding to a decrease in 
the use of HRT.5 The rapid decrease in breast cancer 
incidence reported in these studies suggests that with-
drawal of hormone therapy leads to a regression of 
preclinical cancers.6
In the first 2 years of the oestrogen plus progestogen 
versus placebo arm of the women’s health initiative 
study, fewer breast cancers were diagnosed in the 
women taking combined HRT than in those taking 
placebo. This finding is thought to be the result of 
increases in breast density induced by the hormones, 
making the mammograms harder to interpret and 
causing delay in diagnosis. Thereafter, the number of 
cases of breast cancer increased for the women on 
HRT (hazard ratio 1.26, 95% CI 1.02 to 1.55), and 
the cancers being diagnosed were larger and more 
advanced than those in women not on HRT.4 After 
discontinuation, follow-up of the women who had 
stopped HRT showed that the raised risk of breast 
cancer in this group had decreased rapidly: the risk 
was 28% less in the first post-intervention year despite 
a similar frequency of mammography.6
The increased risk was mainly in women who had 
used oestrogen and progestogen before joining the study 
(1.96, 1.17 to 3.27), as the risk was considerably lower 
in those who had not used these hormones (1.02, 0.77 
to 1.35). There was, however, a significant and increas-
ing trend in the risk of breast cancer with follow-up 
time among women with no previous hormone use. 
 Ongoing use for durations only slightly longer than 5 
years does seem to be associated with an increased risk 
of breast cancer in women who have not previously used 
hormones.4 The combined analysis of the clinical and 
Because adherence to treatment for osteoporosis is 
poor, it could be argued that monitoring bone mineral 
density is justified because it should improve adherence 
and thereby maximise efficacy. We have no evidence to 
support this, however, and it would be difficult to iden-
tify people who do not adhere to this test because of the 
large measurement variability. Because non-adherence 
occurs mostly within the first three months of starting 
treatment, early intervention would probably be more 
effective, and evidence exists that an interview with a 
healthcare professional a few months after starting treat-
ment improves adherence.10 11 Biochemical markers of 
bone turnover could potentially be used for monitoring 
because they change rapidly in response to treatment 
and are more predictive of fracture reduction. However, 
at present within person variability and measurement 
variability are too great for these markers to be useful 
in clinical practice.12 
If true non-responders to antiresorptive treatment do 
exist they are rare, and most cases of non-response are 
caused by failure to persist with treatment. This is best 
tackled by carefully explaining the treatment to patients 
before they start and follow-up after about three months 
to discuss problems related to treatment. Routine moni-
toring of bone mineral density during the first few years 
of antiresorptive treatment cannot be justified because 
it may mislead patients, lead to inappropriate manage-
ment decisions, and waste scarce healthcare resources.
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observational women’s health initiative 
studies also suggests that women who 
initiate oestrogen plus progestogen 
soon after menopause and continue for 
many years seem to be at particularly 
high risk of breast cancer.7
The combined analysis of the 
 clinical and observational results 
also looked at the effect of “gap 
time”—that is, the time from meno-
pause to first use of hormones. This 
analysis showed that the decreased 
risk of breast cancer associated with 
oestrogen therapy only occurred if 
the hormone was used later in the 
post-menopausal period and not 
around the time of menopause.8 Breast cancers make 
adaptive changes during periods of oestrogen depri-
vation such as menopause, and this response subse-
quently decreases the likelihood that the cancer will 
respond to stimulation with oestrogen later in the 
 post-menopausal period.8
The oestrogen only arm of the women’s health initia-
tive found a reduced but not significant difference in 
the incidence of invasive breast cancer in the hormone 
group compared with the placebo group (0.80, 0.62 to 
1.04). Much of this possible decrease in risk is a result 
of the inclusion of women who had not used oestrogen 
before study entry.8 
Other reasons for the decrease in breast cancer diag-
noses have been discussed—for example, a change in 
the number of women undergoing mammographic 
screening or alterations in modifiable risk factors such 
as body mass index. Neither of these appear to be the 
explanation, however, as on the whole the number 
of women undergoing mammography has remained 
constant, and modifiable risk factors have not changed 
appreciably.1 2 3
Given the association between breast cancer and 
HRT use, can women at high risk of breast cancer 
use hormones? Women with mutations in the BRCA1 
or BRAC2 gene have an increased risk of breast and 
ovarian cancer and are advised to have prophylactic 
oophorectomy after having children. This measure 
reduces the risk of ovarian cancer by 90% and breast 
cancer by 50%. Short term observational studies suggest 
that hormone use following bilateral oophorectomy does 
not alter the reduction in the risk of breast cancer associ-
ated with the surgery.9 This result may be a false negative 
finding, however, similar to the initial low incidence of 
breast cancer in the combined arm of the women’s health 
initiative owing to delay in detection.9 
Only 10% of all breast cancers are hereditary and 
only half of these cases are caused by known mutations 
in the BRCA1 and BRAC2 genes. Predictive models—
such as the Gail model, part of the breast cancer risk 
assessment tool of the National Cancer Institute—can 
be used to estimate the risk of breast cancer. An analy-
sis of the oestrogen only arm of the women’s health 
initiative suggested a higher incidence of breast cancer 
with hormone use for those women at high risk of 
breast cancer according to the Gail 
model.8 Caution is therefore advised 
in prescribing hormone therapy to 
women who are already at high risk 
of breast cancer.
For women diagnosed with breast 
cancer chemotherapy, ovarian abla-
tion, and adjuvant therapy can all 
contribute to the occurrence of 
severe flushes. Clinical trials compar-
ing hormone replacement therapy 
and tibolone with placebo in women 
with previous breast cancer found 
increased breast cancer recurrence 
for those women using hormones. 
Hormone use following breast can-
cer treatment should thus be avoided.10 11
Placebo controlled randomised trials have found that 
clonidine, gabapentin, selective serotonin reuptake inhib-
itors, and selective noradrenaline reuptake inhibitors can 
reduce hot flushes. The antidepressant drug venlaflaxine 
seems to interfere less than other antidepressants with the 
efficacy of tamoxifen. Vitamin E can be tried in women 
wishing to avoid taking pharmaceutical agents.12 
These recent reports of a reduction in the incidence 
of breast cancer following a drop in hormone use, along 
with the results from ongoing analyses of the women’s 
health initiative studies, support the use of the lowest 
dose of hormones for the shortest period of time for the 
relief of menopausal flushes. This approach will not only 
decrease the risk of hormone related breast cancers in 
the individual, but also the risk for entire populations.
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